Drug Profile
Research programme: antibody therapeutics - Torch Biosciences/XOMA
Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Torch Biosciences; XOMA
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for research development in Unspecified in USA
- 04 Oct 2017 XOMA Corporation enters into a non-exclusive license agreement with Torch Biosciences for use of its proprietary phage display libraries for antibody discovery and development
- 04 Oct 2017 Early research in Undefined indication in USA (unspecified route)